

Company Flash

17 April 2007 | 9 pages

HCL Technologies (HCLT.B0)

Buy: Another Strong Quarter

- Q3FY07 surprises positively Q3FY07 surprised positively yet again with a revenue 9.6% qoq growth (\$ term). Margins increased yet again to 23.3%. Over the last 4 quarters, HCL Tech's revenues (\$ term) and EBITDA (excluding non cash charges) have increased at a CQGR of 9.6% and 10.1%, respectively.
- All segments performing well Q3 was another quarter of all round growth IT Services witnessed a growth of 8.2% qoq, BPO grew 18.4% qoq while infrastructure services revenues increased 8.1% qoq (all \$ terms).
- EBITDA margins expand again EBITDA margins expanded by ~110 bps qoq again (after a 40bp improvement in 2Q). All segments reported improved profitability IT services margins improved 85bp qoq while BPO margins improved 360bp qoq. Margin expansion was due to improved realizations, lower SG&A, better utilizations partly offset by currency and wage hike in BPO.
- Net profits growth of 16% qoq EBITDA growth was 13% qoq (excluding non cash charges). Higher other income resulted in net profits growing by 16% qoq.
- Expect consensus upgrades; maintain Buy (1M) With a 10% surprise on our numbers and a significant surprise on the street numbers as well consensus upgrades are likely. HCL Tech's large deal strategy is paying off qoq volatility has come down over the last few quarters. The stock trades at 16.6x FY08E we reiterate our Buy/Medium Risk rating.

Buy/Medium Risk	1 M
Price (17 Apr 07)	Rs301.90
Target price	Rs385.00
Expected share price return	27.5%
Expected dividend yield	2.6%
Expected total return	30.2%
Market Cap	Rs200,366M
	US\$4,796M

Statistical Abstract									
Year to	Net Profit	Diluted EPS	EPS growth	P/E	P/B	ROE	Yield		
30 Jun	(RsM)	(Rs)	(%)	(x)	(x)	(%)	(%)		
2005A	6,104	9.56	9.1	31.6	2.5	18.1	1.7		
2006A	7,091	10.46	9.4	28.9	4.8	18.1	2.6		
2007E	10,496	15.40	47.2	19.6	4.3	24.3	2.6		
2008E	12,460	18.23	18.4	16.6	3.7	25.3	29.1		
2009E	14,995	21.94	20.3	13.8	3.2	26.3	2.6		

Surendra Goyal, CFA¹

+91-22-6631-9870 surendra.goyal@citigroup.com

Hitesh Shah¹

+91-22-6631-9872 hitesh.b.shah@citigroup.com

See Appendix A-1 for Analyst Certification and important disclosures.

Citigroup Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Non-US research analysts who have prepared this report are not registered/qualified as research analysts with the NYSE and/or NASD.

¹Citigroup Global Market India Private Limited

Other key points

- EBITDA growth strong EBITDA growth was 13% qoq (excluding non cash charges). Higher other income resulted in net profits growing by 16% qoq. At a company level, the positive drivers for margins were SG&A (+90bp), realizations (+75bp), utilization (+20bp) while the negative drivers were currency (-54bp) and wage increase in BPO (-15bp) netting off to ~125bp increase in margins.
- Hiring remains strong HCL Tech hired ~1800 employees in the quarter over the last 4 quarters, HCL Tech has added 34% to its employee base. HCL Tech has also made campus offers to 5000 candidates.
- Volume growth in IT services muted Volume growth in IT services (3.9% gog) was muted.
- Average realizations in software up 4% Implied pricing in software services increased by 4% qoq. Management indicated that 1.7% increase was on account of higher realization, 1.7% was due to mix change (higher onsite) and remaining was a non-effort based increase.
- Margins improved in IT Services at ~80bp The margin expansion was on account of higher utilization (+20bp), higher realizations (+84bp) and reduced SG&A (+50bp) being offset by negative impact of currency (-64bp).
- Europe/Asia pacific report strong growth US revenues grew 6% in \$ terms while Europe and Asia Pacific delivered very strong growth of 12.5% and 26% respectively. ANZ (Australia/New Zealand) revenue growth was 16.3% qoq.
- Microvertical strategy paying off Aerospace, which is one of the focus microverticals, has witnessed a growth of 95% yoy. Lifescience also witnessed a growth of 90% yoy.
- HCL Tech announces 6 deal wins HCL Tech announced 6 large deal wins one of them is >\$50m in size and another 5 in the rage \$25-50m. 4 of them are in Hi-tech manufacturing and 2 in BFSI.
- Attrition Attrition in IT Services declined marginally from 17.8% in Q2 to 17.5% in Q3 (on a TTM basis). BPO attrition (of employees greater than 6 months experience) increased to 8.8% (from 5.9% in the previous quarter).
- DSO's down again DSO's now stand at 68 as against 70 days at the end of the prior quarter.
- Unrealized treasury gains Unrealized treasury gains at the end of the quarter stand at \$18.1m (as against \$15.3m at the end of previous quarter).
- ESOP charge ESOP charge to be \$22.8m this year and \$22m for FY08.
- Wage hikes HCL Tech management expects wage hikes of 12-15% for offshore employees while onsite wage hikes are expected to be 3-5%. HCL Tech indicated that campus wages have been increased 15% yoy (from Rs. 220,000 per annum last year).
- Forex cover increased HCL Tech has increased the forex cover to ~\$900m as compared to \$515m at the end of the previous quarter.

Figure 1. Key Financials, Rs mn

	3Q06	2Q07	3Q07	QoQ	YoY
Revenue (US\$ m)	252	331	362	9.5%	44.1%
Revenue	11,220	14,651	15,771	7.6%	40.6%
Cost of revenue	6,978	9,107	9,738	6.9%	39.6%
Gross profit	4,242	5,544	6,033	8.8%	42.2%
Gross margin	37.8%	37.8%	38.3%	41bp	45Ьр
Operating expenses	1,744	2,303	2,366	2.7%	35.7%
EBITDA	2,498	3,241	3,667	13.1%	46.8%
EBITDA margin	<i>22.3%</i>	22.1%	<i>23.3%</i>	113bp	99bp
Depreciation and amortization	530	623	659	5.8%	24.3%
EBIT	1,968	2,618	3,008	14.9%	52.8%
EBIT margin	<i>17.5%</i>	17. 9 %	<i>19.1%</i>	120bp	153bp
Other income	255	481	615	27.9%	141.2%
Profit before tax	2,223	3,099	3,623	16.9%	63.0%
Income tax expense	277	206	283	n.a.	2.2%
Income from operations	1,946	2,893	3,340	15.5%	71.6%
Affiliates/Minority	-17	-30	-23	n.a.	n.a.
Net income — before option charges	1,929	2,863	3,317	15.9%	72.0%
Non-cash charges	-183	-266	-304	n.a.	n.a.
Net profit	1,747	2,597	3,013	16.0%	72.5%
EPS - basic	3.01	4.41	5.10	15.5%	69.6%
EPS - diluted	2.88	4.19	4.83	15.3%	67.9%

Source: Company Reports

Figure 2. Segment wise results

	1Q06	2Q06	3Q06	4Q06	1Q07	2Q07	3Q07
HCL Tech - consolidated							
Revenue (Rs mn)	9,710	10,542	11,220	12,538	13,794	14,651	15,771
Change - qoq		8.6%	6.4%	11.7%	10.0%	6.2%	7.6%
EBITDA margin	22.2%	22.5%	22.3%	22.5%	21.7%	22.1%	23.3%
Change - qoq		<i>32bp</i>	-28bp	19Ьр	-78bp	45bp	113bp
IT services							
Revenue (Rs mn)	7,434	8,001	8,348	9,301	10,206	10,739	11,421
Change - qoq		7.6%	4.3%	11.4%	9.7%	5.2%	6.4%
EBITDA margin	22.8%	22.9%	23.5%	23.2%	22.3%	22.9%	23.7%
Change - qoq		14bp	58bp	-24bp	- <i>98bp</i>	62bp	85bp
Infrastructure services							
Revenue (Rs mn)	969	1202	1307	1565	1825	2053	2186
Change - qoq		24.0%	8.7%	19.7%	16.6%	12.5%	6.5%
EBITDA margin	12.6%	15.1%	15.4%	17.4%	17.6%	17.5%	17.6%
Change - qoq		247Ьр	32bp	207Ьр	14bp	-10bp	13Ьр
BPO services							
Revenue (Rs mn)	1,307	1,339	1,565	1,672	1,763	1,859	2,164
Change - qoq		2.4%	16.9%	6.8%	5.4%	5.4%	16.4%
EBITDA margin	26.3%	27.2%	21.5%	22.8%	22.4%	22.9%	26.5%
Change - qoq		86bp	-565bp	125bp	-38bp	51bp	361bp
Source: Company Reports							

Figure 3. Key HR metrics

	1Q06	2Q06	3Q06	4Q06	1 Q 07	2Q07	3Q07
Total manpower	26,285	28,182	29,948	32,626	36,402	38,317	40,149
Net addition	2,198	1,897	1,766	2,678	3,776	1,915	1,832
A. Software services							
Total manpower	17,708	17,793	18,623	20,332	21,943	22,523	23,796
Delivery	16,116	16,020	16,616	18,156	19,657	20,004	21,013
Support	1,592	1,773	2,007	2,176	2,286	2,519	2,783
B. BPO services							
Total manpower	6,772	8,334	8,903	9,343	11,062	12,181	12,354
Delivery	6,228	7,533	8,149	8,596	10,340	11,343	11,407
Support	544	801	754	747	722	838	947
C. Infrastructure services							
Total manpower	1,805	2,055	2,422	2,951	3,397	3,613	3,999
Delivery	1,403	1,670	2,018	2,466	2,867	3,071	3,418
Support	402	385	404	485	530	542	581

Source: Company Reports

Figure	4	Κev	Execution	metrics
LIZUI C	4.	VC A	EXECUTION	111611169

	1Q06	2Q06	3Q06	4Q06	1Q07	2Q07	3Q07
Efforts							
Billed	34,875	37,521	39,304	40,953	42,213	46,264	48,053
- offshore	26,200	28,174	29,150	30,093	30,593	33,986	34,965
- onsite	8,675	9,347	10,154	10,860	11,620	12,278	13,088
Unbilled	9,728	10,154	9,463	9,100	10,055	12,177	12,361
Trainees	4,350	2,259	2,253	3,402	5,853	3,414	3,351
Utilization							
Offshore	67.0%	70.4%	72.6%	71.8%	67.9%	69.4%	69.8%
offshore ex trainees	75.4%	76.4%	76.9%	78.1%	77.7%	74.6%	74.8%
Onsite	88.1%	94.1%	93.5%	94.2%	92.2%	95.2%	95.6%
Revenue Mix							
- offshore	49.5%	50.6%	48.2%	48.6%	48.2%	49.0%	47.7%
- onsite	50.5%	49.4%	51.8%	51.4%	51.8%	51.0%	52.3%
Attrition							
IT services - LTM	17.6%	19.5%	17.8%	16.9%	16.5%	17.8%	17.5%
BPO - quarterly	n.a.	14.2%	15.8%	16.7%	18.5%	19.9%	19.5%
Infrastructure services - LTM	26.0%	23.6%	20.0%	13.7%	13.1%	16.8%	16.4%
Causas Camananu Danasta							

Source: Company Reports

Figure 5. Revenue Mix

	1Q06	2Q06	3Q06	4Q06	1Q07	2Q07	3Q07
Service Offering							
R&D and Engg services	24.1%	23.4%	23.6%	23.9%	24.0%	24.2%	23.3%
Enterprise Application services	18.2%	18.2%	17.0%	12.5%	13.7%	12.7%	13.2%
Application services	34.3%	34.3%	33.9%	37.8%	36.2%	36.3%	35.8%
Infrastructure services	10.0%	11.4%	11.6%	12.5%	13.3%	14.0%	13.8%
BPO services	13.4%	12.7%	14.0%	13.3%	12.8%	12.7%	13.7%
Geography							
US	61.9%	60.6%	59.3%	57.8%	59.6%	57.3%	54.3%
Europe	22.3%	21.4%	25.7%	28.8%	28.6%	29.2%	30.2%
AsiaPac	15.8%	18.0%	15.0%	13.3%	11.8%	13.5%	15.5%
Verticals							
BFSI	n.a.	25.6%	24.3%	n.a.	22.8%	27.2%	27.5%
Manufacturing, Hi-Tech	n.a.	34.2%	33.1%	n.a.	31.3%	29.7%	28.9%
Telecom	n.a.	17.3%	18.5%	n.a.	16.9%	16.2%	17.2%
Retail	n.a.	5.7%	7.7%	n.a.	12.0%	10.6%	9.4%
Media and Entertainment	n.a.	6.1%	6.1%	n.a.	5.9%	5.9%	5.6%
Life Sciences	n.a.	3.4%	3.4%	n.a.	3.5%	4.0%	4.5%
Others	n.a.	7.8%	7.0%	n.a.	7.6%	6.4%	6.8%

Source: Company Reports

Figure 6. Key client metrics

	1Q06	2Q06	3006	4Q06	1Q07	2007	3Q07
Client relationships							
No. of 1 mn \$ clients	140	130	131	133	143	145	147
No. of 5 mn \$ clients	29	33	34	35	41	46	48
No. of 10 mn \$ clients	16	16	14	15	18	22	25
No. of 20 mn \$ clients	5	6	6	6	8	8	10
No. of 50 mn \$ clients	2	2	2	2	2	2	3
Client concentration							
Top 5 Clients	29.9%	28.7%	28.3%	28.1%	28.7%	29.7%	29.2%
Top 10 Clients	39.0%	37.8%	37.6%	37.2%	38.2%	39.0%	38.5%
Top 20 Clients	50.2%	48.6%	48.1%	48.9%	49.9%	51.5%	50.9%

Source: Company Reports

HCL Technologies

Company description

HCL Tech is the fifth-largest Indian IT services company. Founded in 1991, HCL Tech focused on technology and R&D outsourcing before diversifying into enterprise applications. In the infrastructure business, it has been gradually shifting focus from domestic sales to global services. In BPO, it is third-largest offshore services provider and boasts strong ties with British Telecom and SBC. The company leverages off its extensive offshore infrastructure and its global network of 26 offices in 15 countries to deliver solutions across verticals including Banking, Insurance, Retail & Consumer, Aerospace, Automotive, Semiconductors, Telecom and Life Sciences. HCL Tech has over 400 clients across verticals and a workforce of 32,000.

Investment thesis

We rate HCL Tech as Buy/Medium (1M) Risk. Based on our analysis, offshore IT services demand will remain strong with industry revenues forecast to grow 25-30% pa over the next four years. HCL Tech has been at the forefront of pursuing large deals. It has won at least four multi-year US\$50m-plus deals for the past fiscal year. Significant presence across IT services, BPO services and IMS has helped HCL Tech to qualify for multi-year outsourcing deals. Infrastructure-management services, R&D and BPO service offerings should enable it to post strong revenue growth for the next few years. We forecast a 24.3% revenue CAGR and 21.2% EPS CAGR for FY06-09. The stock has underperformed the Sensex for the past two quarters. A forecast dividend yield of 2.9% and high cash per share of Rs58 should limit the downside for this stock.

Valuation

Our 12-month target price is Rs385 based on 19x average FY08-09E EPS. We value HCL Tech relative to Satyam, which is similar to HCL Tech in terms of revenue. We expect a 21.2% CAGR in earnings for the next three years and believe the stock should trade toward the high end of its historical three-year trading range of 14-23x 12-month forward earnings. HCL Tech has traded on a par with Satyam in the past two years. Our P/E target is based on a 10% discount to our target multiple of 21x for Satyam primarily because of lower growth and return ratios compared with Satyam. We believe P/E remains the most appropriate valuation measure given HCL Tech's past profitability and future earnings visibility. Our target price is also supported by average FY08-09E Price/Sales of 3.1x, which is within the stock's historical trading range of 2-4x.

Risks

We rate HCL Tech as Medium Risk based on our quantitative risk-rating system, which tracks 260-day historical share price volatility. The key downside risks that could impede the stock from reaching our target price include: (1) significant qoq volatility in growth rates; (2) any significant appreciation of the rupee against the US dollar/euro/pound; (3) a sharp slowdown in the US economy; (4) a slowdown in the banking, financial services and insurance (BFSI) sector; (5) H1B visa quotas; (6) acquisition-related risks; and (7) the strategy of pursuing large deals could have negative margin implications.

Appendix A-1

Analyst Certification

We, Surendra Goyal, CFA and Hitesh Shah, research analysts and the authors of this report, hereby certify that all of the views expressed in this research report accurately reflect our personal views about any and all of the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

IMPORTANT DISCLOSURES

Citigroup Global Markets Inc. or an affiliate received compensation for products and services other than investment banking services from HCL Technologies in the past 12 months.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, securities-related: HCL Technologies.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, non-securities-related: HCL Technologies.

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability, which includes revenues from, among other business units, the Private Client Division, Institutional Sales and Trading, and Investment Banking.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citigroup Investment Research product ("the Product"), please contact Citigroup Investment Research, 388 Greenwich Street, 29th Floor, New York, NY, 10013, Attention: Legal/Compliance. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at www.citigroupgeo.com. Private Client Division clients should refer to www.smithbarney.com/research. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

Citigroup Investment Research Ratings Distribution			
Data current as of 31 March 2007	Buy	Hold	Sell
Citigroup Investment Research Global Fundamental Coverage (3215)	45%	40%	15%
% of companies in each rating category that are investment banking clients	45%	42%	32%
India Asia Pacific (130)	58%	14%	28%
% of companies in each rating category that are investment banking clients	42%	50%	42%

Guide to Fundamental Research Investment Ratings:

Citigroup Investment Research's stock recommendations include a risk rating and an investment rating.

Risk ratings, which take into account both price volatility and fundamental criteria, are: Low (L), Medium (M), High (H), and Speculative (S).

Investment ratings are a function of Citigroup Investment Research's expectation of total return (forecast price appreciation and dividend yield within the next 12 months) and risk rating.

For securities in emerging markets (Asia Pacific, Emerging Europe/Middle East/Africa, and Latin America), investment ratings are: Buy (1) (expected total return of 15% or more for Low-Risk stocks, 20% or more for Medium-Risk stocks, 30% or more for High-Risk stocks, and 40% or more for Speculative stocks); Hold (2) (5%-15% for Low-Risk stocks, 10%-20% for Medium-Risk stocks, 15%-30% for High-Risk stocks, and 20%-40% for Speculative stocks); and Sell (3) (5% or less for Low-Risk stocks, 10% or less for Medium-Risk stocks, 15% or less for High-Risk stocks, and 20% or less for Speculative stocks).

Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At other times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected performance and risk.

17 April 2007

http://deadpresident.blogspot.com

Citigroup Investment Research's corporate bond research issuer publications include a fundamental credit opinion of Improving, Stable or Deteriorating and a complementary risk rating of Low (L), Medium (M), High (H) or Speculative (S) regarding the credit risk of the company featured in the report. The fundamental credit opinion reflects the CIR analyst's opinion of the direction of credit fundamentals of the issuer without respect to securities market vagaries. The fundamental credit opinion is not geared to, but should be viewed in the context of debt ratings issued by major public debt ratings companies such as Moody's Investors Service, Standard and Poor's, and Fitch Ratings.

CBR risk ratings are approximately equivalent to the following matrix:

Low Risk -- Triple A to Low Double A Low to Medium Risk -- High Single A through High Triple B Medium to High Risk -- Mid Triple B through High Double B High to Speculative Risk -- Mid Double B and Below

The risk rating element illustrates the analyst's opinion of the relative likelihood of loss of principal when a fixed-income security issued by a company is held to maturity. based upon both fundamental and market risk factors. Certain reports published by Citigroup Investment Research will also include investment ratings on specific issues of companies under coverage which have been assigned fundamental credit opinions and risk ratings. Investment ratings are a function of Citigroup Investment Research's expectations for total return, relative return (to publicly available Citigroup bond indices performance), and risk rating. These investment ratings are: Buy/Overweight -- the bond is expected to outperform the relevant Citigroup bond market sector index (Broad Investment Grade, High Yield Market or Emerging Market), performances of which are updated monthly and can be viewed at http://www.sd.ny.ssmb.com/ using the "Indexes" tab; Hold/Neutral Weight -- the bond is expected to perform in line with the relevant Citigroup bond market sector index; or Sell/Underweight -- the bond is expected to underperform the relevant sector of the Citigroup indexes.

OTHER DISCLOSURES

The subject company's share price set out on the front page of this Product is quoted as at 17 April 2007 03:44 PM on the issuer's primary market.

Citigroup Global Markets Inc. or its affiliates holds a long position in any class of common equity securities of HCL Technologies.

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the subject company(ies) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citigroup Investment Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citigroup Investment Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product must take into account existing public information on such security or any registered prospectus.

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

The Citigroup legal entity that takes responsibility for the product in the Product is the legal entity which the first named author is employed by. The Product is made available in Australia to wholesale clients through Citigroup Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992) and to retail clients through Citigroup Wealth Advisors Pty Ltd. (ABN 19 009 145 555 and AFSL No. 240813), Participants of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. If the Product is being made available in certain provinces of Canada by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. The Product may not be distributed to private clients in Germany. The Product is distributed in Germany. by Citigroup Global Markets Deutschland AG & Co. KGaA, which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). Frankfurt am Main, Reuterweg 16, 60323 Frankfurt am Main. If the Product is made available in Hong Kong by, or on behalf of, Citigroup Global Markets Asia Ltd., it is attributable to Citigroup Global

Markets Asia Ltd., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Product is made available in Hong Kong by The Citigroup Private Bank to its clients, it is attributable to Citibank N.A., Citibank Tower, Citibank Plaza, 3

Garden Road, Hong Kong. The Citigroup Private Bank and Citibank N.A. is regulated by the Hong Kong Monetary Authority. The Product is made available in India by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. If the Product was prepared by Citigroup Investment Research and distributed in Japan by Nikko Citigroup Ltd., it is being so distributed under license. Nikko Citigroup Limited is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Akasaka Park Building, 2-20, Akasaka 5-chome, Minato-ku, Tokyo 107-6122. The Product is made available in Korea by Citigroup Global Markets Korea Securities Ltd., which is regulated by Financial Supervisory Commission and the Financial Supervisory Service. Hungkuk Life Insurance Building, 226 Shinmunno 1-GA, Jongno-Gu, Seoul, 110-061. The Product is made available in Malaysia by Citigroup Global Markets Malaysia Sdn Bhd, which is regulated by Malaysia Securities Commission. Menara Citibank, 165 Jalan Ampang, Kuala Lumpur, 50450. The Product is made available in Mexico by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, which is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In New Zealand the Product is made available through Citigroup Global Markets New Zealand Ltd., a Participant of the New Zealand Exchange Limited and regulated by the New Zealand Securities Commission. Level 19, Mobile on the Park, 157 lambton Quay, Wellington. The Product is made available in Poland by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Papierów Wartosciowych i Gield. Bank Handlowy w Warszawie S.A. ul. Senatorska 16, 00-923 Warszawa. The Product is made available in the Russian Federation through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in Singapore through Citigroup Global Markets Singapore Pte. Ltd., a Capital Markets Services Licence holder, and regulated by Monetary Authority of Singapore. 1 Temasek Avenue, #39-02 Millenia Tower, Singapore 039192. The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Citigroup Global Markets (Pty) Ltd. is incorporated in the Republic of South Africa (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in Taiwan through Citigroup Global Markets Inc. (Taipei Branch), which is regulated by Securities & Futures Bureau. No portion of the report may be reproduced or quoted in Taiwan by the press or any other person. No. 8 Manhattan Building, Hsin Yi Road, Section 5, Taipei 100, Taiwan. The Product is made available in Thailand through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in United Kingdom by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in United States by Citigroup Global Markets Inc, which is regulated by NASD, NYSE and the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority. Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citigroup Investment Research's Products can be found at www.citigroupgeo.com. Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations. The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would be illegal. Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. Advice in the Product has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs.

© 2007 Citigroup Global Markets Inc. Citigroup Investment Research is a division and service mark of Citigroup Global Markets Inc. and its affiliates and is used and registered throughout the world. Citigroup and the Umbrella Device are trademarks and service marks of Citigroup or its affiliates and are used and registered throughout the world. Nikko is a registered trademark of Nikko Cordial Corporation. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST